Hospital oncology pharmacy (HOP) is evolving in tandem with the rapid pace of oncology research, encompassing breakthroughs in anticancer therapies, the management of treatment-related toxicities, and the application of novel methodologies for evaluating therapeutic strategies. This paper presents a synthesis on these topics, based in part, on the latest scientific event organized by the French society for oncology pharmacy (SFPO), known as St. Louis’ Day. During this event, seven leading experts — comprising medical oncologists and HOPs — engaged in in-depth discussions on three pivotal themes: the assessment of therapeutic innovations, recent progress in cancer-related vaccinology, and the management of immune-related adverse events. The proceedings underscore the critical role of HOPs as key members of the interdisciplinary oncology team, driving ongoing advancements in the quality and safety of cancer care.
Le pharmacien hospitalier en oncologie est pleinement intégré au rythme rapide des évolutions de la recherche, englobant les progrès thérapeutiques, la prise en charge des toxicités liées aux traitements anticancéreux et la mise en place de nouvelles méthodologies d’évaluation des stratégies thérapeutiques. Cet article présente une synthèse de ces sujets basée, en partie, sur le dernier évènement scientifique organisé par la Société française de pharmacie oncologique (SFPO), « La journée de Saint Louis ». Durant cet évènement, sept experts de premier plan – oncologues médicaux et pharmaciens hospitaliers en oncologie – ont engagé des discussions sur trois thèmes pivots : évaluation des innovations thérapeutiques, vaccinologie anticancéreuse et toxicités des immunothérapies. Les débats ont pointé le rôle essentiel des pharmaciens hospitaliers en oncologie en tant que membres des équipes interdisciplinaires conduisant les progrès continus dans la qualité et la sécurité de la prise en charge du malade présentant un cancer.
{"title":"The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care","authors":"Florence Ranchon , Florian Slimano , Maha Ayyoub , Charlotte Bérard , Anais Grand , Marie Kroemer , Xavier Paoletti , Vérane Schwiertz , Pascale Tomasini , Christophe Bardin , Emmanuel Raffoux , Catherine Rioufol , Régine Chevrier , Bertrand Pourroy , Jean-Louis Cazin","doi":"10.1016/j.pharma.2025.10.001","DOIUrl":"10.1016/j.pharma.2025.10.001","url":null,"abstract":"<div><div>Hospital oncology pharmacy (HOP) is evolving in tandem with the rapid pace of oncology research, encompassing breakthroughs in anticancer therapies, the management of treatment-related toxicities, and the application of novel methodologies for evaluating therapeutic strategies. This paper presents a synthesis on these topics, based in part, on the latest scientific event organized by the French society for oncology pharmacy (SFPO), known as St. Louis’ Day. During this event, seven leading experts — comprising medical oncologists and HOPs — engaged in in-depth discussions on three pivotal themes: the assessment of therapeutic innovations, recent progress in cancer-related vaccinology, and the management of immune-related adverse events. The proceedings underscore the critical role of HOPs as key members of the interdisciplinary oncology team, driving ongoing advancements in the quality and safety of cancer care.</div></div><div><div>Le pharmacien hospitalier en oncologie est pleinement intégré au rythme rapide des évolutions de la recherche, englobant les progrès thérapeutiques, la prise en charge des toxicités liées aux traitements anticancéreux et la mise en place de nouvelles méthodologies d’évaluation des stratégies thérapeutiques. Cet article présente une synthèse de ces sujets basée, en partie, sur le dernier évènement scientifique organisé par la Société française de pharmacie oncologique (SFPO), « La journée de Saint Louis ». Durant cet évènement, sept experts de premier plan – oncologues médicaux et pharmaciens hospitaliers en oncologie – ont engagé des discussions sur trois thèmes pivots : évaluation des innovations thérapeutiques, vaccinologie anticancéreuse et toxicités des immunothérapies. Les débats ont pointé le rôle essentiel des pharmaciens hospitaliers en oncologie en tant que membres des équipes interdisciplinaires conduisant les progrès continus dans la qualité et la sécurité de la prise en charge du malade présentant un cancer.</div></div>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 1","pages":"Pages 69-77"},"PeriodicalIF":1.1,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div><h3>Objectifs</h3><div>L’objectif de ce travail est de proposer une formation complète sur le circuit des dispositifs médicaux stériles (DMS) au bloc opératoire (BO) à l’aide d’un livret exhaustif ainsi que par la mise en place d’une évaluation des connaissances à destination des infirmières de bloc opératoire et des préparateurs en pharmacie hospitalière.</div></div><div><h3>Méthodes</h3><div>La rédaction de chaque partie du livret s’est appuyée sur les documents internes de qualité relatifs au circuit des DMS de notre centre et a fait l’objet d’une validation institutionnelle. Un questionnaire à choix multiples basé sur ce livret a été réalisé.</div></div><div><h3>Résultats</h3><div>Le livret apporte une réponse claire et précise sur le rôle de chacun en cas d’interrogations ponctuelles. Le questionnaire de 62 items devait être réalisé avant et après lecture du livret. Sur les 21 participants, une diminution globale du nombre d’erreurs de 58,5 % après lecture du livret a été mise en évidence. Les soignants en poste depuis plus d’un an ont fait en moyenne 9,9 erreurs [1–17], et 14 erreurs [8–21] pour ceux présents depuis moins d’un an.</div></div><div><h3>Conclusions</h3><div>Le livret développé en équipe pluridisciplinaire a été apprécié par l’ensemble des corps de métiers intervenants au BO sur le circuit des DMS. Il a contribué à harmoniser et éclaircir le rôle de chacun dans les différents circuits propres aux DMS. La mise au point d’un questionnaire d’évaluation a permis de cibler les principales difficultés sur lesquelles une formation complémentaire sera organisée. Les résultats de ces questionnaires ont objectivé la pertinence de la lecture de cet ouvrage.</div></div><div><h3>Objectives</h3><div>The objective of this work is to provide comprehensive training on the workflow of sterile medical devices (SMDs) in the operating room (OR) with the help of an exhaustive booklet and the introduction of an evaluation to assess OR nurses and hospital pharmacy technicians knowledge.</div></div><div><h3>Methods</h3><div>Each section of the booklet was written based on internal quality documents related to the SMD workflow at our hospital and was institutionally validated. A multiple-choice questionnaire based on the booklet was developed.</div></div><div><h3>Results</h3><div>The booklet provides a clear and precise explanation of each person's role when specific questions arise. The 62-item questionnaire was to be completed before and after reading the booklet. Among the 21 participants, an overall reduction in errors of 58.5% after reading the booklet was observed. Staff who have been in their position for more than a year made an average of 9.9 errors [1–17], compared to 14 errors [8–21] for those with less than one year of experience.</div></div><div><h3>Conclusions</h3><div>The booklet, developed by a multidisciplinary team, was well received by all professionals involved in the SMD workflow within the OR. It helped clarify and harmonize e
{"title":"Rédaction d’un livret d’accueil du nouvel arrivant au bloc opératoire : circuit des dispositifs médicaux stériles et mise en place d’un questionnaire d’évaluation","authors":"Lola Kazek, Isabelle Denis, Marwane Azizi, Morgane Cessiecq, Aude Capelle","doi":"10.1016/j.pharma.2025.09.001","DOIUrl":"10.1016/j.pharma.2025.09.001","url":null,"abstract":"<div><h3>Objectifs</h3><div>L’objectif de ce travail est de proposer une formation complète sur le circuit des dispositifs médicaux stériles (DMS) au bloc opératoire (BO) à l’aide d’un livret exhaustif ainsi que par la mise en place d’une évaluation des connaissances à destination des infirmières de bloc opératoire et des préparateurs en pharmacie hospitalière.</div></div><div><h3>Méthodes</h3><div>La rédaction de chaque partie du livret s’est appuyée sur les documents internes de qualité relatifs au circuit des DMS de notre centre et a fait l’objet d’une validation institutionnelle. Un questionnaire à choix multiples basé sur ce livret a été réalisé.</div></div><div><h3>Résultats</h3><div>Le livret apporte une réponse claire et précise sur le rôle de chacun en cas d’interrogations ponctuelles. Le questionnaire de 62 items devait être réalisé avant et après lecture du livret. Sur les 21 participants, une diminution globale du nombre d’erreurs de 58,5 % après lecture du livret a été mise en évidence. Les soignants en poste depuis plus d’un an ont fait en moyenne 9,9 erreurs [1–17], et 14 erreurs [8–21] pour ceux présents depuis moins d’un an.</div></div><div><h3>Conclusions</h3><div>Le livret développé en équipe pluridisciplinaire a été apprécié par l’ensemble des corps de métiers intervenants au BO sur le circuit des DMS. Il a contribué à harmoniser et éclaircir le rôle de chacun dans les différents circuits propres aux DMS. La mise au point d’un questionnaire d’évaluation a permis de cibler les principales difficultés sur lesquelles une formation complémentaire sera organisée. Les résultats de ces questionnaires ont objectivé la pertinence de la lecture de cet ouvrage.</div></div><div><h3>Objectives</h3><div>The objective of this work is to provide comprehensive training on the workflow of sterile medical devices (SMDs) in the operating room (OR) with the help of an exhaustive booklet and the introduction of an evaluation to assess OR nurses and hospital pharmacy technicians knowledge.</div></div><div><h3>Methods</h3><div>Each section of the booklet was written based on internal quality documents related to the SMD workflow at our hospital and was institutionally validated. A multiple-choice questionnaire based on the booklet was developed.</div></div><div><h3>Results</h3><div>The booklet provides a clear and precise explanation of each person's role when specific questions arise. The 62-item questionnaire was to be completed before and after reading the booklet. Among the 21 participants, an overall reduction in errors of 58.5% after reading the booklet was observed. Staff who have been in their position for more than a year made an average of 9.9 errors [1–17], compared to 14 errors [8–21] for those with less than one year of experience.</div></div><div><h3>Conclusions</h3><div>The booklet, developed by a multidisciplinary team, was well received by all professionals involved in the SMD workflow within the OR. It helped clarify and harmonize e","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 1","pages":"Pages 141-146"},"PeriodicalIF":1.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-16DOI: 10.1016/j.pharma.2025.08.006
Md. Mojeeb G. Khan , Shubham R. Raut , Md. Rageeb Md. Usman , Atul A. Shirkhedkar , Md. Shamsher Alam , Zamir G. Khan
<div><h3>Objectives</h3><div>The primary objective was to develop and validate four novel UV/visible spectrophotometric methods for the quantification of tafamidis meglumine in bulk drug, proprietary capsules, and spiked urine samples, ensuring accuracy, sensitivity, and environmental sustainability for pharmaceutical analysis.</div></div><div><h3>Methods</h3><div>Four spectrophotometric approaches were established using absorbance and area under the curve (AUC) measurements, employing both zero-order and first-order derivative techniques. Method validation followed ICH guidelines, assessing linearity, accuracy, precision, sensitivity (LOD, LOQ), and greenness. Methanol was used as a green solvent, and eco-friendliness was evaluated using AGREE and ComplexGAPI metrics.</div></div><div><h3>Results</h3><div>All methods exhibited excellent linearity (R<sup>2</sup> <!-->=<!--> <!-->0.9980–0.9995) over a 3–18<!--> <!-->μg/mL range. Accuracy was confirmed with recovery rates between 99.00% and 100.57%. Precision studies yielded %RSD values below 2%, indicating high reproducibility. Sensitivity was demonstrated with LOD and LOQ values from 0.27<!--> <!-->μg/mL to 2.3<!--> <!-->μg/mL. The use of methanol minimized environmental impact, and high AGREE and ComplexGAPI scores validated the methods’ eco-friendly nature.</div></div><div><h3>Conclusion</h3><div>The developed spectrophotometric methods are simple, rapid, sensitive, and environmentally sustainable for quantifying tafamidis meglumine in various matrices. These validated approaches set a new standard for green analytical chemistry in pharmaceutical quality control, ensuring both regulatory compliance and reduced environmental footprint.</div></div><div><h3>Objectifs</h3><div>L’objectif principal était de développer et valider quatre nouvelles méthodes spectrophotométriques UV/Visible pour la quantification du méglumine de tafamidis dans la substance pure, les gélules commerciales et les échantillons d’urine dopés, en garantissant précision, sensibilité et durabilité environnementale pour l’analyse pharmaceutique.</div></div><div><h3>Méthodes</h3><div>Quatre approches spectrophotométriques ont été établies en utilisant les mesures d’absorbance et de surface sous la courbe (AUC), avec des techniques dérivées d’ordre zéro et de premier ordre. La validation des méthodes a suivi les lignes directrices ICH, évaluant la linéarité, l’exactitude, la précision, la sensibilité (LOD, LOQ) et l’écocompatibilité. Le méthanol a été utilisé comme solvant vert, et l’impact environnemental a été évalué à l’aide des métriques AGREE et ComplexGAPI.</div></div><div><h3>Résultats</h3><div>Toutes les méthodes ont montré une excellente linéarité (R<sup>2</sup> <!-->=<!--> <!-->0,9980–0,9995) sur une plage de 3–18<!--> <!-->μg/mL. L’exactitude a été confirmée avec des taux de récupération entre 99,00 % et 100,57 %. Les études de précision ont donné des valeurs de %RSD inférieures à 2 %, indiquant une reproductibilité élev
{"title":"Optimization of UV spectrophotometric techniques for tafamidis meglumine detection in pharmaceutical formulations and biological samples: A green chemistry perspective","authors":"Md. Mojeeb G. Khan , Shubham R. Raut , Md. Rageeb Md. Usman , Atul A. Shirkhedkar , Md. Shamsher Alam , Zamir G. Khan","doi":"10.1016/j.pharma.2025.08.006","DOIUrl":"10.1016/j.pharma.2025.08.006","url":null,"abstract":"<div><h3>Objectives</h3><div>The primary objective was to develop and validate four novel UV/visible spectrophotometric methods for the quantification of tafamidis meglumine in bulk drug, proprietary capsules, and spiked urine samples, ensuring accuracy, sensitivity, and environmental sustainability for pharmaceutical analysis.</div></div><div><h3>Methods</h3><div>Four spectrophotometric approaches were established using absorbance and area under the curve (AUC) measurements, employing both zero-order and first-order derivative techniques. Method validation followed ICH guidelines, assessing linearity, accuracy, precision, sensitivity (LOD, LOQ), and greenness. Methanol was used as a green solvent, and eco-friendliness was evaluated using AGREE and ComplexGAPI metrics.</div></div><div><h3>Results</h3><div>All methods exhibited excellent linearity (R<sup>2</sup> <!-->=<!--> <!-->0.9980–0.9995) over a 3–18<!--> <!-->μg/mL range. Accuracy was confirmed with recovery rates between 99.00% and 100.57%. Precision studies yielded %RSD values below 2%, indicating high reproducibility. Sensitivity was demonstrated with LOD and LOQ values from 0.27<!--> <!-->μg/mL to 2.3<!--> <!-->μg/mL. The use of methanol minimized environmental impact, and high AGREE and ComplexGAPI scores validated the methods’ eco-friendly nature.</div></div><div><h3>Conclusion</h3><div>The developed spectrophotometric methods are simple, rapid, sensitive, and environmentally sustainable for quantifying tafamidis meglumine in various matrices. These validated approaches set a new standard for green analytical chemistry in pharmaceutical quality control, ensuring both regulatory compliance and reduced environmental footprint.</div></div><div><h3>Objectifs</h3><div>L’objectif principal était de développer et valider quatre nouvelles méthodes spectrophotométriques UV/Visible pour la quantification du méglumine de tafamidis dans la substance pure, les gélules commerciales et les échantillons d’urine dopés, en garantissant précision, sensibilité et durabilité environnementale pour l’analyse pharmaceutique.</div></div><div><h3>Méthodes</h3><div>Quatre approches spectrophotométriques ont été établies en utilisant les mesures d’absorbance et de surface sous la courbe (AUC), avec des techniques dérivées d’ordre zéro et de premier ordre. La validation des méthodes a suivi les lignes directrices ICH, évaluant la linéarité, l’exactitude, la précision, la sensibilité (LOD, LOQ) et l’écocompatibilité. Le méthanol a été utilisé comme solvant vert, et l’impact environnemental a été évalué à l’aide des métriques AGREE et ComplexGAPI.</div></div><div><h3>Résultats</h3><div>Toutes les méthodes ont montré une excellente linéarité (R<sup>2</sup> <!-->=<!--> <!-->0,9980–0,9995) sur une plage de 3–18<!--> <!-->μg/mL. L’exactitude a été confirmée avec des taux de récupération entre 99,00 % et 100,57 %. Les études de précision ont donné des valeurs de %RSD inférieures à 2 %, indiquant une reproductibilité élev","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 1","pages":"Pages 124-140"},"PeriodicalIF":1.1,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-07DOI: 10.1016/j.pharma.2025.08.001
Oluwaseun E. Agboola , Samuel S. Agboola , Othuke B. Odeghe , Oluranti E. Olaiya , Zainab A. Ayinla , Priscilla O. Akinsanya , Olutosin S. Ilesanmi , Tobi K. Ibrahim , Theophilus A. Adegbuyi , Oyebamiji Abel Kolawole , Idowu O. Omotuyi , Babatunji E. Oyinloye
The convergence of precision medicine strategies, CRISPR gene editing technologies, and artificial intelligence (AI) is causing a revolutionary change in the pharmaceutical industry in recent times. Latest trends and future directions of these integrated technologies in pharmaceutical science and molecular biology are presented in the present exhaustive review. With more than 250 gene-editing clinical trials being tracked internationally as of February 2025, the recent clinical successes point toward the therapeutic potency of CRISPR-based therapeutics. In parallel, AI-based drug discovery platforms are recording fantastic hit rates; compared to conventional industry benchmarks, AI-emerging drugs reflect 80–90% Phase I trial success rates. Therapeutic development paradigms are being transformed by the intersection of machine learning algorithms, multi-omics technologies, and precision medicine paradigms. The review provides insights into the revolutionary potential of these converging approaches in addressing unmet medical requirements and optimizing therapeutic benefits through syntheses of existing evidence from clinical trials, regulatory matters, and technological innovations.
La convergence des stratégies de médecine de précision, des technologies d’édition génique CRISPR et de l’intelligence artificielle (IA) provoque actuellement un changement révolutionnaire dans l’industrie pharmaceutique. Cette revue exhaustive présente les tendances récentes et les orientations futures de ces technologies intégrées en sciences pharmaceutiques et en biologie moléculaire. Avec plus de 250 essais cliniques d’édition génique suivis à l’échelle internationale en février 2025, les récents succès cliniques témoignent du potentiel thérapeutique des traitements basés sur CRISPR. Parallèlement, les plateformes de découverte de médicaments basées sur l’IA enregistrent des taux de réussite fantastiques; comparés aux références industrielles conventionnelles, les médicaments émergents de l’IA reflètent des taux de succès de 80 à 90 % pour les essais de Phase I. Les paradigmes de développement thérapeutique sont transformés par l’intersection des algorithmes d’apprentissage automatique, des technologies multi-omiques et des paradigmes de médecine de précision. Cette revue fournit des perspectives sur le potentiel révolutionnaire de ces approches convergentes pour répondre aux besoins médicaux non satisfaits et optimiser les bénéfices thérapeutiques grâce à la synthèse des preuves existantes issues d’essais cliniques, de questions réglementaires et d’innovations technologiques.
{"title":"Computational genome engineering through AI-CRISPR-precision medicine integration in modern therapeutics","authors":"Oluwaseun E. Agboola , Samuel S. Agboola , Othuke B. Odeghe , Oluranti E. Olaiya , Zainab A. Ayinla , Priscilla O. Akinsanya , Olutosin S. Ilesanmi , Tobi K. Ibrahim , Theophilus A. Adegbuyi , Oyebamiji Abel Kolawole , Idowu O. Omotuyi , Babatunji E. Oyinloye","doi":"10.1016/j.pharma.2025.08.001","DOIUrl":"10.1016/j.pharma.2025.08.001","url":null,"abstract":"<div><div>The convergence of precision medicine strategies, CRISPR gene editing technologies, and artificial intelligence (AI) is causing a revolutionary change in the pharmaceutical industry in recent times. Latest trends and future directions of these integrated technologies in pharmaceutical science and molecular biology are presented in the present exhaustive review. With more than 250 gene-editing clinical trials being tracked internationally as of February 2025, the recent clinical successes point toward the therapeutic potency of CRISPR-based therapeutics. In parallel, AI-based drug discovery platforms are recording fantastic hit rates; compared to conventional industry benchmarks, AI-emerging drugs reflect 80–90% Phase I trial success rates. Therapeutic development paradigms are being transformed by the intersection of machine learning algorithms, multi-omics technologies, and precision medicine paradigms. The review provides insights into the revolutionary potential of these converging approaches in addressing unmet medical requirements and optimizing therapeutic benefits through syntheses of existing evidence from clinical trials, regulatory matters, and technological innovations.</div></div><div><div>La convergence des stratégies de médecine de précision, des technologies d’édition génique CRISPR et de l’intelligence artificielle (IA) provoque actuellement un changement révolutionnaire dans l’industrie pharmaceutique. Cette revue exhaustive présente les tendances récentes et les orientations futures de ces technologies intégrées en sciences pharmaceutiques et en biologie moléculaire. Avec plus de 250 essais cliniques d’édition génique suivis à l’échelle internationale en février 2025, les récents succès cliniques témoignent du potentiel thérapeutique des traitements basés sur CRISPR. Parallèlement, les plateformes de découverte de médicaments basées sur l’IA enregistrent des taux de réussite fantastiques; comparés aux références industrielles conventionnelles, les médicaments émergents de l’IA reflètent des taux de succès de 80 à 90 % pour les essais de Phase I. Les paradigmes de développement thérapeutique sont transformés par l’intersection des algorithmes d’apprentissage automatique, des technologies multi-omiques et des paradigmes de médecine de précision. Cette revue fournit des perspectives sur le potentiel révolutionnaire de ces approches convergentes pour répondre aux besoins médicaux non satisfaits et optimiser les bénéfices thérapeutiques grâce à la synthèse des preuves existantes issues d’essais cliniques, de questions réglementaires et d’innovations technologiques.</div></div>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 6","pages":"Pages 1073-1085"},"PeriodicalIF":1.1,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div><h3>Objectives</h3><div>Glioblastoma (GBM) is one of the most aggressive and treatment-resistant types of brain cancer, and conventional therapies such as surgery, chemotherapy, and radiotherapy have limited effectiveness in controlling it. In this context, the use of natural compounds with anticancer properties has been explored as a complementary strategy. The purpose of the current study was to assess the cytotoxic and pro-apoptotic potential of the plant extracts <em>Echium amoenum</em> and <em>Valeriana officinalis</em> in U87-MG glioblastoma cells.</div></div><div><h3>Materials and methods</h3><div>The Maceration technique was used to prepare the plant extracts. U87-MG cells and L-929 cell lines were cultured and treated with various concentrations (31.25, 62.5, 125, 250, 500 and 1000<!--> <!-->μg/mL) of the extracts upon reaching optimal confluence. An MTT assay was performed to evaluate the cytotoxicity at 24, 48 and 72<!--> <!-->hours. To investigate the expression of apoptosis-related genes (<em>Bax</em>, <em>Bcl-2</em> and <em>Caspase-3</em>, <em>Caspase-9</em> and <em>puma</em>), RNA was extracted and converted to cDNA and then the expression of these genes was analyzed by real-time PCR.</div></div><div><h3>Results</h3><div>MTT assay results showed that both extracts inhibited cancer cell growth in a dose- and time-dependent manner. At 72<!--> <!-->hours and a concentration of 1000<!--> <!-->μg/mL, <em>E. amoenum</em> extract exhibited the highest inhibition rate (96%), while <em>V. officinalis</em> extract showed 95% inhibition under the same conditions. At the molecular level, <em>E. amoenum</em> extract significantly upregulated <em>Caspase-3</em> expression by more than 20-fold (<em>P</em> <!--><<!--> <!-->0.0001) indicating a strong activation of the apoptotic pathway, while <em>V. officinalis</em> extract did not cause a significant change in the expression of this gene. Additionally, <em>Bcl-2</em> expression was significantly elevated in the <em>E. amoenum</em>-treated group (<em>P</em> <!--><<!--> <!-->0.001). However, the upregulation of <em>Bcl-2</em>—a gene associated with cell survival—was considerably weaker compared to the robust induction of <em>Caspase-3</em>. Also, <em>E. amoenum</em> significantly upregulated <em>Caspase-9</em> expression (<em>P</em> <!--><<!--> <!-->0.0001), indicating activation of the intrinsic apoptotic pathway.</div></div><div><h3>Conclusion</h3><div>The results demonstrated that extracts from <em>V. officinalis</em> and <em>E. amoenum</em> have anticancer effects on U87-MG cells, possibly through the induction of apoptosis. <em>E. amoenum</em> was more effective in raising <em>Caspase-3</em> and initiating pathways leading to programmed cell death, whereas <em>V. officinalis</em> did not change the expression levels of apoptotic genes. Our finding suggests that this plant may exert its anticancer effects through non-apoptotic or alternative apoptotic mechanisms, rather than the c
{"title":"Comparative evaluation of the anticancer effects of Echium amoenum and Valeriana officinalis on U87-MG glioblastoma cells","authors":"Maryam Mohseni , Reza Masoomi Jahandizi , Ehsan Zayerzadeh","doi":"10.1016/j.pharma.2025.08.003","DOIUrl":"10.1016/j.pharma.2025.08.003","url":null,"abstract":"<div><h3>Objectives</h3><div>Glioblastoma (GBM) is one of the most aggressive and treatment-resistant types of brain cancer, and conventional therapies such as surgery, chemotherapy, and radiotherapy have limited effectiveness in controlling it. In this context, the use of natural compounds with anticancer properties has been explored as a complementary strategy. The purpose of the current study was to assess the cytotoxic and pro-apoptotic potential of the plant extracts <em>Echium amoenum</em> and <em>Valeriana officinalis</em> in U87-MG glioblastoma cells.</div></div><div><h3>Materials and methods</h3><div>The Maceration technique was used to prepare the plant extracts. U87-MG cells and L-929 cell lines were cultured and treated with various concentrations (31.25, 62.5, 125, 250, 500 and 1000<!--> <!-->μg/mL) of the extracts upon reaching optimal confluence. An MTT assay was performed to evaluate the cytotoxicity at 24, 48 and 72<!--> <!-->hours. To investigate the expression of apoptosis-related genes (<em>Bax</em>, <em>Bcl-2</em> and <em>Caspase-3</em>, <em>Caspase-9</em> and <em>puma</em>), RNA was extracted and converted to cDNA and then the expression of these genes was analyzed by real-time PCR.</div></div><div><h3>Results</h3><div>MTT assay results showed that both extracts inhibited cancer cell growth in a dose- and time-dependent manner. At 72<!--> <!-->hours and a concentration of 1000<!--> <!-->μg/mL, <em>E. amoenum</em> extract exhibited the highest inhibition rate (96%), while <em>V. officinalis</em> extract showed 95% inhibition under the same conditions. At the molecular level, <em>E. amoenum</em> extract significantly upregulated <em>Caspase-3</em> expression by more than 20-fold (<em>P</em> <!--><<!--> <!-->0.0001) indicating a strong activation of the apoptotic pathway, while <em>V. officinalis</em> extract did not cause a significant change in the expression of this gene. Additionally, <em>Bcl-2</em> expression was significantly elevated in the <em>E. amoenum</em>-treated group (<em>P</em> <!--><<!--> <!-->0.001). However, the upregulation of <em>Bcl-2</em>—a gene associated with cell survival—was considerably weaker compared to the robust induction of <em>Caspase-3</em>. Also, <em>E. amoenum</em> significantly upregulated <em>Caspase-9</em> expression (<em>P</em> <!--><<!--> <!-->0.0001), indicating activation of the intrinsic apoptotic pathway.</div></div><div><h3>Conclusion</h3><div>The results demonstrated that extracts from <em>V. officinalis</em> and <em>E. amoenum</em> have anticancer effects on U87-MG cells, possibly through the induction of apoptosis. <em>E. amoenum</em> was more effective in raising <em>Caspase-3</em> and initiating pathways leading to programmed cell death, whereas <em>V. officinalis</em> did not change the expression levels of apoptotic genes. Our finding suggests that this plant may exert its anticancer effects through non-apoptotic or alternative apoptotic mechanisms, rather than the c","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 1","pages":"Pages 90-100"},"PeriodicalIF":1.1,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-06DOI: 10.1016/j.pharma.2025.08.005
Alma Feka , Mario Verdugo-Marchese , Sarah Hugelshofer , Stéphane Guerrier , Nancy Perrottet , Matthias Kirsch , Farshid Sadeghipour , Ziyad Gunga
<div><h3>Objectives</h3><div>The objective of this study was to assess whether implementing a protocol could improve adherence to European guidelines on postoperative antithrombotic therapy prescription in patients undergoing coronary artery bypass-grafts surgery (CABG) after acute coronary syndrome (ACS).</div></div><div><h3>Methods</h3><div>We included patients who underwent cardiac surgery between January 2018 and December 2022. The population was divided in two groups, one before (group 1) and one after (group 2) the dissemination of a protocol on postoperative antithrombotic therapy issued by a multidisciplinary collaboration (January 2021) and its subsequent implementation during ward rounds. We analysed the protocol's impact on adherence to European guidelines in terms of antithrombotic therapy at discharge.</div></div><div><h3>Results</h3><div>We included 259 patients, 83.8% were men and the median age was 67 [58; 74] years. At baseline, group 1 (<em>n</em> <!-->=<!--> <!-->152) and group 2 (<em>n</em> <!-->=<!--> <!-->107) had similar demographic characteristics except for smoking status and ACS events. Patients in group 2 had a higher rate of guideline adherence in terms of postoperative antithrombotic therapy (group 1<!--> <!-->=<!--> <!-->58.6% vs. group 2<!--> <!-->=<!--> <!-->82.2%, <em>P</em> <!--><<!--> <!-->0.001). Using logistic regression accounting for demographic and temporal factors, the effect of the intervention was positive but not statistically significant. Adherence increased significantly over time, suggesting that the intervention contributed to an overall trend of improved adherence as apart of ongoing quality improvement efforts.</div></div><div><h3>Conclusion</h3><div>Implementing the protocol was associated with a positive effect on guideline adherence for postoperative antithrombotic therapy in ACS patients undergoing CABG. Although the intervention's independent effect was not statistically significant after adjustment, the findings support its role in achieving sustained improvement in adherence over time.</div></div><div><h3>Objectif</h3><div>L’objectif de cette étude était d’évaluer si la mise en place d’un protocole pouvait améliorer l’observance des recommandations européennes sur la prescription d’un traitement antithrombotique postopératoire chez les patients opérés d’un pontage aorto-coronarien (PAC) après un syndrome coronarien aigu (SCA).</div></div><div><h3>Méthodes</h3><div>Nous avons inclus les patients ayant subi une chirurgie cardiaque entre janvier 2018 et décembre 2022. La population a été divisée en deux groupes, l’un avant (groupe 1) et l’autre après (groupe 2) la diffusion d’un protocole sur le traitement antithrombotique postopératoire émis par une collaboration multidisciplinaire (janvier 2021) et sa mise en œuvre ultérieure lors des visites médicales dans le service. Nous avons analysé l’impact du protocole sur l’adhésion aux recommandations européennes en termes de traitement antithrom
{"title":"A multidisciplinary intervention to improve postoperative antithrombotic therapy after urgent coronary artery bypass-grafts","authors":"Alma Feka , Mario Verdugo-Marchese , Sarah Hugelshofer , Stéphane Guerrier , Nancy Perrottet , Matthias Kirsch , Farshid Sadeghipour , Ziyad Gunga","doi":"10.1016/j.pharma.2025.08.005","DOIUrl":"10.1016/j.pharma.2025.08.005","url":null,"abstract":"<div><h3>Objectives</h3><div>The objective of this study was to assess whether implementing a protocol could improve adherence to European guidelines on postoperative antithrombotic therapy prescription in patients undergoing coronary artery bypass-grafts surgery (CABG) after acute coronary syndrome (ACS).</div></div><div><h3>Methods</h3><div>We included patients who underwent cardiac surgery between January 2018 and December 2022. The population was divided in two groups, one before (group 1) and one after (group 2) the dissemination of a protocol on postoperative antithrombotic therapy issued by a multidisciplinary collaboration (January 2021) and its subsequent implementation during ward rounds. We analysed the protocol's impact on adherence to European guidelines in terms of antithrombotic therapy at discharge.</div></div><div><h3>Results</h3><div>We included 259 patients, 83.8% were men and the median age was 67 [58; 74] years. At baseline, group 1 (<em>n</em> <!-->=<!--> <!-->152) and group 2 (<em>n</em> <!-->=<!--> <!-->107) had similar demographic characteristics except for smoking status and ACS events. Patients in group 2 had a higher rate of guideline adherence in terms of postoperative antithrombotic therapy (group 1<!--> <!-->=<!--> <!-->58.6% vs. group 2<!--> <!-->=<!--> <!-->82.2%, <em>P</em> <!--><<!--> <!-->0.001). Using logistic regression accounting for demographic and temporal factors, the effect of the intervention was positive but not statistically significant. Adherence increased significantly over time, suggesting that the intervention contributed to an overall trend of improved adherence as apart of ongoing quality improvement efforts.</div></div><div><h3>Conclusion</h3><div>Implementing the protocol was associated with a positive effect on guideline adherence for postoperative antithrombotic therapy in ACS patients undergoing CABG. Although the intervention's independent effect was not statistically significant after adjustment, the findings support its role in achieving sustained improvement in adherence over time.</div></div><div><h3>Objectif</h3><div>L’objectif de cette étude était d’évaluer si la mise en place d’un protocole pouvait améliorer l’observance des recommandations européennes sur la prescription d’un traitement antithrombotique postopératoire chez les patients opérés d’un pontage aorto-coronarien (PAC) après un syndrome coronarien aigu (SCA).</div></div><div><h3>Méthodes</h3><div>Nous avons inclus les patients ayant subi une chirurgie cardiaque entre janvier 2018 et décembre 2022. La population a été divisée en deux groupes, l’un avant (groupe 1) et l’autre après (groupe 2) la diffusion d’un protocole sur le traitement antithrombotique postopératoire émis par une collaboration multidisciplinaire (janvier 2021) et sa mise en œuvre ultérieure lors des visites médicales dans le service. Nous avons analysé l’impact du protocole sur l’adhésion aux recommandations européennes en termes de traitement antithrom","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 1","pages":"Pages 114-123"},"PeriodicalIF":1.1,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号